Cabergoline Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cabergoline Supply in 2026

If your patients have been reporting difficulty filling Cabergoline prescriptions, their experience reflects a broader pattern. While Cabergoline is not currently on the FDA's formal Drug Shortage Database, intermittent supply disruptions have become a recurring issue — driven by a limited manufacturer base and the niche nature of this medication.

This briefing covers what you need to know about the current supply landscape, prescribing implications, and tools that can help your patients maintain access to treatment.

Timeline: How We Got Here

Cabergoline's supply challenges aren't new, but they've become more noticeable in recent years:

• 2019–2021: Periodic reports of pharmacy-level stockouts, primarily at chain retail pharmacies. No formal FDA shortage listing.
• 2022–2023: Broader supply chain disruptions post-pandemic affected many generic medications, including those with limited manufacturer pools like Cabergoline.
• 2024–2025: Intermittent availability issues continued. Patients increasingly reported having to search multiple pharmacies or switch to Bromocriptine temporarily.
• 2026 (current): Production continues from major generic manufacturers, but distribution remains uneven. Not FDA-listed as a shortage, but real-world access difficulties persist.

The core issue is structural: Cabergoline is an ergot-derived compound with complex synthesis requirements, produced by only a few generic manufacturers (primarily Teva Pharmaceuticals). This creates inherent vulnerability to supply disruptions.

Prescribing Implications

As the prescribing provider, you may need to adapt your approach during periods of limited availability:

Prescription Quantity

Consider writing 90-day prescriptions when clinically appropriate. Since Cabergoline is dosed twice weekly (standard maintenance: 0.5 mg to 1 mg twice weekly), a 90-day supply is approximately 26 tablets — a small quantity that should be manageable for pharmacies to source.

Pharmacy Selection

Guide patients toward pharmacies more likely to stock or source Cabergoline:

• Independent pharmacies with multiple wholesaler relationships
• Specialty pharmacies experienced with endocrine medications
• Hospital outpatient pharmacies that may receive priority allocation
• Mail-order pharmacies with larger generic inventories

Alternative Therapy Planning

Have a documented plan for each Cabergoline patient in case supply becomes unavailable:

• Bromocriptine (Parlodel) is the primary alternative. Dosing: 1.25–2.5 mg BID or TID, titrated to prolactin levels. Meta-analyses show Cabergoline normalizes prolactin in ~83% of patients versus ~59% for Bromocriptine, but Bromocriptine remains clinically effective for many patients.
• Dose adjustment period: When transitioning from Cabergoline to Bromocriptine, monitor prolactin levels at 4 and 8 weeks to confirm adequate suppression.
• Quinagolide is a non-ergot option available outside the United States but is not FDA-approved.

Current Availability Picture

As of March 2026:

• FDA shortage status: Not listed
• ASHP shortage status: No active listing
• Generic manufacturers: Teva Pharmaceuticals (primary), with limited additional producers
• Dosage form: 0.5 mg oral tablet (scored)
• Real-world availability: Uneven. Larger pharmacies and mail-order services tend to have more consistent stock. Smaller retail pharmacies may have difficulty sourcing.

Cost and Access Considerations

Cost can be a barrier, particularly for uninsured patients:

• Generic cash price: $50–$200+ for 8 tablets (0.5 mg) without a coupon
• With discount coupons (GoodRx, SingleCare): $24–$45 for 8 tablets
• Insurance coverage: Most commercial and Medicaid plans cover generic Cabergoline. Prior authorization is uncommon but may be required by some plans.
• Patient assistance: No dedicated manufacturer PAP exists for generic Cabergoline. Refer patients to NeedyMeds or RxAssist for general assistance resources.

For a patient-facing resource on cost savings, you can share: How to Save Money on Cabergoline in 2026.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that allows you and your staff to check real-time pharmacy availability for Cabergoline by location. This can be integrated into your clinical workflow to proactively identify pharmacies with stock before the patient leaves the office.

Patient Education Materials

Consider directing patients to these resources:

• How to Find Cabergoline in Stock Near You — practical pharmacy search strategies
• Alternatives to Cabergoline — what patients should know about Bromocriptine and other options
• Cabergoline Side Effects — what to expect and when to call the doctor

Echocardiogram Monitoring Reminder

Per current FDA labeling, providers should:

• Perform a baseline echocardiogram before initiating Cabergoline
• Monitor with echocardiogram every 6–12 months during treatment
• Evaluate promptly if patients develop new onset edema, cardiac murmur, dyspnea, or other symptoms suggestive of valvular disease

This monitoring schedule applies to Cabergoline and should be considered when switching patients to Bromocriptine (also an ergot derivative with similar, though less pronounced, fibrotic risk).

Looking Ahead

The structural factors driving Cabergoline's supply challenges — few manufacturers, complex synthesis, niche demand — are unlikely to change rapidly. However, several developments could improve the situation:

• Additional generic manufacturers entering the market
• Improved supply chain tracking and distribution tools
• Growing adoption of pharmacy availability platforms like Medfinder

In the meantime, proactive communication with patients, documented alternative therapy plans, and awareness of current availability tools will help minimize treatment disruptions.

Final Thoughts

Cabergoline remains the first-line therapy for hyperprolactinemia, and its clinical advantages over Bromocriptine are well-established. The current supply challenges don't change the treatment algorithm — they change the logistics. Equipping your practice with the right tools and having alternative plans in place ensures your patients maintain access to effective treatment.

For a practical guide on helping patients navigate pharmacy availability, see How to Help Your Patients Find Cabergoline in Stock.